Evidence map›Paper›PMID 41348225›Full record

ArticleArchives of virology2025

Immunogenetic insights into matching bivalent inactivated Payavax G79® for sustainable poultry vaccination against NDV-GVII and H9N2.

Parisa Jamour, Seyed Sajjad Babaeimarzangou, Nima Daneshvar Hosseini, Mostafa Gholizadeh Gigloo, Rasa Sheini Mehrabzadeh, Towhid Mohammadi, Zohre Khademi, Maryam Shafaati

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Parisa JamourAmirabad Virology Laboratory, Vaccine Unit, Tehran, Iran.
Seyed Sajjad BabaeimarzangouDivision of Poultry Health and Diseases, Department of Clinical Sciences, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran.
Nima Daneshvar HosseiniD.V.M Technical Manager of Hafez Dam Toos. Co, Mashhad, Iran.
Mostafa Gholizadeh GiglooVeterinary Clinic Complex of Dr. Gholizadeh, Qazvin, Iran.
Rasa Sheini MehrabzadehVeterinary Clinic Complex of Dr. Gholizadeh, Qazvin, Iran.
Towhid MohammadiAmirabad Virology Laboratory, Vaccine Unit, Tehran, Iran.
Zohre KhademiResearch and Development Department, Paya Vaccine Tavana Company, Alborz, Iran.
Maryam ShafaatiResearch and Development Department, Paya Vaccine Tavana Company, Alborz, Iran. Maryam.shafaati@gmail.com.ORCID http://orcid.org/0000-0002-7401-2237

Funding

Paya Vaccine Tavana Co. 03/008B.
6 · The paper itself

Abstract

Newcastle disease virus (NDV) and H9N2 avian influenza virus (AIV) have a severe impact on the poultry industry. This Iranian study evaluated Payavax G79®, an inactivated bivalent vaccine, in broiler chickens across five provinces. Vaccinated chicks showed robust antibody responses to both viruses via HI tests at 25 and 32 days post-vaccination. The vaccine provided complete protection against challenge with velogenic NDV genotype VII. However, H9N2 infection occurred on three farms, with 2% mortality. Molecular analysis of NDV isolates revealed amino acid substitutions in the hemagglutinin-neuraminidase protein that potentially enhance antigenicity. This study shows that Payavax G79® is highly immunogenic and provides significant protection against both NDV and H9N2 AIV under field conditions in Iran.

Indexed as

Influenza A Virus, H9N2 SubtypeInfluenza in BirdsNewcastle DiseaseNewcastle disease virusPoultry DiseasesViral VaccinesAnimalsAntibodies, ViralChickensIranVaccinationVaccines, InactivatedAntibodies, ViralVaccines, InactivatedViral VaccinesEffectivenessH9N2 avian influenzaImmunogenicityNewcastle disease virusVaccine

Identifiers

PMID41348225

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.